22 May 2026
EMA/CVMP/107543/2026
Committee for Veterinary Medicinal Products

Summary of opinion[1] (initial authorisation)

Poulvac Procerta HVT-ND

Common name: Marek's disease and Newcastle disease vaccine (live recombinant)

On 21 May 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a marketing authorisation for the veterinary medicinal product Poulvac Procerta HVT-ND, concentrate and solvent for suspension for injection, intended for chickens and embryonated chicken eggs. The applicant for this veterinary medicinal product is Zoetis Belgium.

Poulvac Procerta HVT-ND is an immunological veterinary medicinal product containing turkey herpes virus, strain HVT-ND (cell-associated), expressing the F protein gene of Newcastle disease virus (live) (ATCvet code QI01AD) as the active substance. The vaccine induces active immunity against Marek's disease and Newcastle disease in chickens.

The benefits of Poulvac Procerta HVT-ND are its efficacy for active immunisation of one day old chickens and 18-19 day old embryonated chicken eggs to reduce mortality, clinical signs and lesions caused by Marek's disease (MD) virus and to reduce mortality and clinical signs caused by Newcastle disease (ND) virus.

The onset of immunity is 9 days post vaccination for *in ovo* and subcutaneous use for MD and 24 days post vaccination for *in ovo* and 21 days for subcutaneous use for ND. The duration of immunity is 63 days of age for ND. A single vaccination is sufficient to provide protection for the entire risk period for MD.

Poulvac Procerta HVT-ND is generally well tolerated at the recommended dose. No symptoms were observed after the administration of a 10-fold dose of the vaccine.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Poulvac Procerta HVT-ND and therefore recommends the granting of the marketing authorisation.